Abstracts Archive - Page 2063 of 2607 - ACR Meeting Abstracts

Abstract Number: 2558 • 2014 ACR/ARHP Annual Meeting
Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures
M.a.C. van der Weijden^1,2, J.C. van Denderen², W.F. Lems¹, M.T. Nurmohamed^1,2, B.a.C Dijkmans^1,2 and I.E. van der Horst-Bruinsma¹, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose Ankylosing spondylitis (AS) is characterized by chronic inflammation often leading to ankylosis of the spine, but also by a decrease of bone mineral density…
Abstract Number: 2557 • 2014 ACR/ARHP Annual Meeting
Are We over-Treating with Nsaids Our Early Axial Spa Patients? Results from the DESIR Cohort
Anna Moltó^1,2, Benjamin Granger³, Daniel Wendling⁴, Maxime Dougados⁵ and Laure Gossec⁶, ¹GRC-UPMC 08 (EEMOIS); UPMC Univ Paris 06.AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France., Paris, France, ²Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ³Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ⁴Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁵INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁶Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are the keystone in the treatment of axial Spondyloarthritis (axSpA), and even in early forms, patients symptoms may lead to…
Abstract Number: 2556 • 2014 ACR/ARHP Annual Meeting
Is the Degree of NSAID Treatment in Early Axial Spondyloarthritis a Reflection of the physician’s Diagnosic Confidence? Results from the DESIR Cohort
Anna Moltó^1,2, Benjamin Granger³, Daniel Wendling⁴, Maxime Dougados⁵ and Laure Gossec⁶, ¹GRC-UPMC 08 (EEMOIS); UPMC Univ Paris 06.AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France., Paris, France, ²Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ³Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ⁴Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁵INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁶Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are the keystone in the treatment of axial Spondyloarthritis (axSpA). Diagnosis is often not easy in early forms due to…
Abstract Number: 2555 • 2014 ACR/ARHP Annual Meeting
The Effect of Co-Medication with Conventional Synthetic (cs)Dmards on Achieving Low Disease Activity While Persisting on Adalimumab Therapy in Patients with Ankylosing Spondylitis/ Axial Spondylarthritis (AS)– Analysis from the Czech Biologics Registry Attra
Karel Pavelka¹, Jakub Zavada², Marketa Fojtikova³, Sarka Forejtova⁴ and Karel Hejduk⁵, ¹Institute of Rheumatology, Prague, Czech Republic, ²Charles University, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁴Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁵Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
Background/Purpose : The role of combined treatment with csDMARDs and anti-TNF therapy in AS is not well established. Methods: Main goal of this study was…
Abstract Number: 2554 • 2014 ACR/ARHP Annual Meeting
Do TNF Alpha Inhibitors Have an NSAID Sparing Effect in Real Life in Early Axial Spa? Results from the DESIR Cohort
Anna Moltó^1,2, Benjamin Granger³, Daniel Wendling⁴, Maxime A. Breban⁵, Maxime Dougados⁶ and Laure Gossec⁷, ¹GRC-UPMC 08 (EEMOIS); UPMC Univ Paris 06.AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France., Paris, France, ²Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ³Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ⁴Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁵Rheumatology, Ambroise Paré Hospital, and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁶INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁷Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are the keystone in the treatment of axial Spondyloarthritis (axSpA), but have potential side effects (cardiovascular and gastrointestinal). Effectiveness of…
Abstract Number: 2573 • 2014 ACR/ARHP Annual Meeting
Preferences of Patients with Spondyloarthritis for the Items of the ASAS Health Index : A Best Worst Scaling
Uta Kiltz¹, Mickaël Hiligsmann², D van der Heijde³, Juergen Braun¹, Alarcos Cieza⁴, Walter P. Maksymowych⁵, William Taylor⁶ and Annelies Boonen⁷, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Psychology, University Southampton, Southampton, United Kingdom, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ⁷Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose The ASAS Health Index (ASAS HI) is a disease-specific questionnaire aiming at measurement of health in patients with spondyloarthritis (SpA) which has been developed…
Abstract Number: 2572 • 2014 ACR/ARHP Annual Meeting
Recognition of Spondyloarthritis By General Practitioners in Daily Practice and the Effect of Education on This; A Study with Standardized Patients
Marloes van Onna¹, Simone Gorter², Bas Maiburg³, Gerrie Waagenaar³ and Astrid van Tubergen⁴, ¹Department of Internal Medicine, division of Rheumatology, Maastricht University Medical Center, division of Rheumatology, Maastricht, Netherlands, ²Department of Internal Medicine, division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of General Practice, Maastricht Univerisity, department of General Practice, Maastricht, Netherlands, ⁴Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Timely recognition and referral of patients with spondyloarthritis (SpA) is challenging due to the insidious disease onset and frequently unawareness of the clinical picture…
Abstract Number: 2571 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Risk of Cardiovascular Disease in Patients with Ankylosing Spondylitis with High and Low Body Mass Index
Inger Jorid Berg¹, Anne Grete Semb², Désirée van der Heijde^3,4, Tore K. Kvien⁴, Hanne Dagfinrud⁴, Jonny Hisdal^5,6 and Sella A. Provan², ¹Dep of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ⁶Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD), but the mediators of this increased risk are not known. Obesity is…
Abstract Number: 2570 • 2014 ACR/ARHP Annual Meeting
Validation of Modified Disease Activity and Functional Status Questionnaires in Spondyloarthritis
Itziar Quinzanos¹, Phat Luong¹, Sushmitha Bobba², J. Steuart Richards³, Vikas Majithia⁴, Lisa A. Davis⁵ and Liron Caplan⁶, ¹Rheumatology, Denver VA Medical Center, Denver, CO, ²Rheumatology/Research, Department of Veterans Affairs, Denver, CO, ³Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ⁴Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ⁵Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ⁶Div of Rheumatology, Denver VA and Univ of Colorado School of Medicine, Aurora, CO
Background/Purpose Patients with new onset ankylosing spondylitis (AS) and those naïve to the Ankylosing Spondylitis Disease Activity Score (ASDAS) have voiced confusion over the use…
Abstract Number: 2569 • 2014 ACR/ARHP Annual Meeting
Profiles of Switches in Patient with Ankylosing Spondylitis: Comparing Adalimumab, Etanercept, Infliximab, Golimumab and Certolizumab
Jean-Pierre Raynauld¹, Louis Bessette², Denis Choquette¹, Isabelle Fortin³, Boulos Haraoui¹, Jean-Pierre Pelletier⁴, Marie-Anaïs Rémillard⁵, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁵Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: As much a 40% of patients with ankylosing spondylitis will fail (BASDAI≥ 4) different non-steroidal anti-inflammatory agents and will eventually be treated with an…
Abstract Number: 2568 • 2014 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data (RAPID3) Provides Similar Information Compared to Ankylosing Spondylitis Specific Indices: Analyses of the DESIR French Cohort
Isabel Castrejón¹, Theodore Pincus¹, Daniel Wendling² and Maxime Dougados³, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Service de Rhumatologie, CHU J Minjoz, Besancon, France, ³Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose The Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI) –an index of only patient-self-report measures - has been the most widely used measure in…
Abstract Number: 2567 • 2014 ACR/ARHP Annual Meeting
Vascular Endothelial Growth Factor and C-Reactive Protein Serum Levels Lack Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with the Tumor Necrosis Factor-Inhibitor Golimumab
Xenofon Baraliakos¹, Kay-Geert A. Hermann², Stephen Xu³, Benjamin Hsu³ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Janssen Research & Development, LLC., Spring House, PA
Background/Purpose Using data from GO-RAISE, we analyzed correlations between serum vascular endothelial growth factor (VEGF) and C-reactive protein (CRP) levels, radiographic progression and inflammation as…
Abstract Number: 2566 • 2014 ACR/ARHP Annual Meeting
Spinal Mobility in the Cervical and the Lumbar Spine Correlates with Magnetic Resonance Imaging Findings in Patients with Ankylosing Spondylitis
Xenofon Baraliakos¹, Kay-Geert A. Hermann², Stephen Xu³, Benjamin Hsu³ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Janssen Research & Development, LLC., Spring House, PA
Background/Purpose Spinal mobility, as assessed by the Bath Ankylosing Spondylitis Metrology Index, BASMI, and imaging findings have been reported to correlate on the group level.…
Abstract Number: 2565 • 2014 ACR/ARHP Annual Meeting
The Effect of DMARD Co-Therapy on the Clinical Efficacy of Anti-TNF Medications in Patients with Axial Spondyloarthritis
Michael J. Nissen¹, Adrian Ciurea², Juerg Bernhard³, Rudiger Muller⁴, Giorgio Tamborrini⁵, Martin Toniolo⁶, Cem Gabay⁷ and Axel Finckh¹, ¹Rheumatology, Geneva University Hospital, Geneva, Switzerland, ²Gloriastrasse 25, Rheumaklinik, Universitatsspital Zurich, Zurich, Switzerland, ³Rheumatology, Solothurn Hospital, Solothurn, Switzerland, ⁴Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁵Department of Rheumatology and Musculoskeletal Ultrasound, Bethesda Hospital Basel, Basel, Switzerland, ⁶Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁷University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland
Background/Purpose: Randomized clinical trials and current recommendations suggest little role for disease-modifying anti-rheumatic drugs (DMARDs) as co-therapy with anti-TNF (aTNF) agents in patients with axial-spondyloarthritis…
Abstract Number: 2562 • 2014 ACR/ARHP Annual Meeting
The Comparative One-Year Drug Survival Rate of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid arthritis and ankylosing spondylitis; results from Turkbio Registry
Ismail Sari¹, Umut Kalyoncu², Ahmet Mesut Onat³, Omer Nuri Pamuk⁴, Omer Karadag², Bunyamin Kisacik³, Niels Steen Krogh⁵, Soner Şenel⁶, Fatih Saritaş⁷, Ihsan Ertenli², Sedat Kiraz², Pinar Cetin¹, Fatos Onen¹ and Nurullah Akkoc¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, ³Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁴Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey, ⁵Consultant, ZiteLab Aps, Copenhagen, Denmark, ⁶Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, ⁷Rheumatology, Trakya University School of Medicine, Edirne, Turkey
Background/Purpose Three different anti–tumor necrosis factor α (anti-TNFα) drugs (infliximab, etanercept, and adalimumab) are approved for patients with rheumatoid arthritis (RA) and particular ankylosing spondylitis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].